Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
torcetrapib/atorvastatin · 9 trials · 8 indications
| Name | Type | Description |
|---|---|---|
| torcetrapib/atorvastatin | DRUG | - |
| simvastatin | DRUG | - |
| atorvastatin | DRUG | - |
| Fenofibrate | DRUG | - |
| placebo | DRUG | - |
Inclusion Criteria: * eligible for statin treatment for LDL cholesterol by NCEP guidelines Exclusion Criteria: * Women who are pregnant or lactating, or planning to become pregnant. * Subjects taking any drugs known to be associated with an increased risk of myositis in combination with HMG-CoA r...
Top 11 of 23 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Novartis AG Sponsored ADR | NVS | 7 | PHASE3 | Inclisiran, YMI024 |
| Novo Nordisk A/S Sponsored ADR Class B | NVO | 4 | PHASE3 | Ziltivekimab |
| Viatris, Inc. | VTRS | 2 | PHASE3 | Selatogrel |
| Alnylam Pharmaceuticals, Inc | ALNY | 1 | PHASE3 | Zilebesiran |
| NewAmsterdam Pharma Company N.V. | NAMS | 1 | PHASE3 | Obicetrapib |
| GE Healthcare Technologies Inc. | GEHC | 3 | PHASE1 | Regadenoson |
| Humacyte, Inc. | HUMA | 1 | PHASE2 | CTEV |
| AstraZeneca PLC | AZN | 1 | - | Tezepelumab |
| Sanofi SA Sponsored ADR | SNY | 2 | - | alirocumab |
| Bayer | BAYRY | 1 | PHASE1 | Nurandociguat |
| Hoffmann-La Roche | RHHBY | 1 | PHASE1 | RO7763505 |
Torcetrapib/atorvastatin is an investigational combination small molecule developed by Pfizer for cardiovascular conditions. It pairs torcetrapib, a CETP inhibitor, with atorvastatin, a statin used to lower cholesterol. It was studied in coronary disease, hypercholesterolemia, familial hyperlipidemia, hyperlipidemia, and hypertriglyceridemia, and remains in Phase 3 development.
Torcetrapib/atorvastatin targets CETP, cholesteryl ester transfer protein. Torcetrapib acts as a CETP inhibitor, while atorvastatin is a statin component that lowers cholesterol. The combination was designed to raise HDL cholesterol through CETP inhibition while lowering LDL cholesterol through the atorvastatin component.
Pfizer, Inc. develops torcetrapib/atorvastatin. Pfizer trades on the New York Stock Exchange under the ticker PFE. The company sponsored the Phase 3 clinical program evaluating the combination in patients with high cholesterol and related lipid disorders.
Torcetrapib/atorvastatin is in Phase 3 development. It is an investigational combination and is not approved. Four Phase 3 trials have been completed, with no active trials ongoing. The completed studies enrolled a total of 5,468 participants across the program.
Four completed Phase 3 trials studied torcetrapib/atorvastatin. NCT00267254 compared it with simvastatin in 640 subjects with high cholesterol. NCT00139061 assessed HDL-C increase and non-HDL lowering versus fenofibrate in 128 subjects in France. NCT00138762 compared it with atorvastatin alone or placebo in 3,800 patients. NCT00137462 compared it with atorvastatin alone in 900 patients.
Torcetrapib/atorvastatin was studied for coronary disease, hypercholesterolemia, familial hyperlipidemia, hyperlipidemia, and hypertriglyceridemia. The Phase 3 trials enrolled adults with high cholesterol and lipid disorders, comparing the combination against simvastatin, fenofibrate, atorvastatin alone, or placebo.